274 related articles for article (PubMed ID: 26515587)
1. A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma.
Jiang SS; Tang Y; Zhang YJ; Weng DS; Zhou ZG; Pan K; Pan QZ; Wang QJ; Liu Q; He J; Zhao JJ; Li J; Chen MS; Chang AE; Li Q; Xia JC
Oncotarget; 2015 Dec; 6(38):41339-49. PubMed ID: 26515587
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
Lee JH; Lee JH; Lim YS; Yeon JE; Song TJ; Yu SJ; Gwak GY; Kim KM; Kim YJ; Lee JW; Yoon JH
Gastroenterology; 2015 Jun; 148(7):1383-91.e6. PubMed ID: 25747273
[TBL] [Abstract][Full Text] [Related]
3. Postoperative immunotherapy for patients with hepatocarcinoma using tumor-infiltrating lymphocytes.
Wang Y; Chen H; Wu M; Bao J; Cong W; Wang H
Chin Med J (Engl); 1997 Feb; 110(2):114-7. PubMed ID: 9594281
[TBL] [Abstract][Full Text] [Related]
4. [Experimental and clinical research of cytolytic T lymphocytes specific for hepatocellular carcinoma].
Shen F; Wang H; Xie T
Zhonghua Wai Ke Za Zhi; 1997 Feb; 35(2):95-9. PubMed ID: 10374486
[TBL] [Abstract][Full Text] [Related]
5. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
Weber J; Atkins M; Hwu P; Radvanyi L; Sznol M; Yee C;
Clin Cancer Res; 2011 Apr; 17(7):1664-73. PubMed ID: 21325070
[TBL] [Abstract][Full Text] [Related]
6. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Hershkovitz L; Levy D; Kubi A; Hovav E; Chermoshniuk N; Shalmon B; Hardan I; Catane R; Markel G; Apter S; Ben-Nun A; Kuchuk I; Shimoni A; Nagler A; Schachter J
Clin Cancer Res; 2010 May; 16(9):2646-55. PubMed ID: 20406835
[TBL] [Abstract][Full Text] [Related]
7. [Cellular immune function influence on postoperative patients with hepatocellular carcinoma and the clinical effect of TILs treatment].
Ba M; He S; Zhang C; Wei D; Zhao Z
Zhonghua Wai Ke Za Zhi; 1999 Jan; 37(1):5-7. PubMed ID: 11829765
[TBL] [Abstract][Full Text] [Related]
8. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
[TBL] [Abstract][Full Text] [Related]
9. The Characteristics of Naive-like T Cells in Tumor-infiltrating Lymphocytes From Human Lung Cancer.
Sheng SY; Gu Y; Lu CG; Tang YY; Zou JY; Zhang YQ; Wang RF; Hong H
J Immunother; 2017 Jan; 40(1):1-10. PubMed ID: 27828929
[TBL] [Abstract][Full Text] [Related]
10. [Perspectives on immunotherapy for hepatocellular carcinoma].
Schmidt N; Büttner N; Thimme R
Dtsch Med Wochenschr; 2013 Apr; 138(14):740-4. PubMed ID: 23533044
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor activity and mechanism of oligoclonal hepatocellular carcinoma tumor-infiltrating lymphocytes
Wang WC; Zhang ZQ; Li PP; Ma JY; Chen L; Qian HH; Shi LH; Yin ZF; Sun B; Zhang XF
Cancer Biol Ther; 2019; 20(9):1187-1194. PubMed ID: 31018748
[No Abstract] [Full Text] [Related]
12. [Effects of auto-tumor infiltrating lymphocytes induced by interleukin (IL)-12 with IL-2 on patients of primary hepatic carcinoma].
Zhang YX; Wang XY; Liu JB; Zhang SQ; Chen YR
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(14):973-6. PubMed ID: 18756970
[TBL] [Abstract][Full Text] [Related]
13. [Study and clinical application of tumor-infiltrating lymphocytes isolated from hepatocarcinoma].
Wang Y; Chen H; Wu M
Zhonghua Wai Ke Za Zhi; 1995 Jan; 33(1):29-31. PubMed ID: 7774441
[TBL] [Abstract][Full Text] [Related]
14. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.
Dudley ME; Gross CA; Somerville RP; Hong Y; Schaub NP; Rosati SF; White DE; Nathan D; Restifo NP; Steinberg SM; Wunderlich JR; Kammula US; Sherry RM; Yang JC; Phan GQ; Hughes MS; Laurencot CM; Rosenberg SA
J Clin Oncol; 2013 Jun; 31(17):2152-9. PubMed ID: 23650429
[TBL] [Abstract][Full Text] [Related]
15. High number of PD-1 positive intratumoural lymphocytes predicts survival benefit of cytokine-induced killer cells for hepatocellular carcinoma patients.
Chang B; Shen L; Wang K; Jin J; Huang T; Chen Q; Li W; Wu P
Liver Int; 2018 Aug; 38(8):1449-1458. PubMed ID: 29356308
[TBL] [Abstract][Full Text] [Related]
16. [HCC: Adoptive immunotherapy promises success].
Krome S
Dtsch Med Wochenschr; 2001 Feb; 126(6):A107-8. PubMed ID: 11233890
[No Abstract] [Full Text] [Related]
17. Prognostic Role of Immune Cells in Hepatitis B-associated Hepatocellular Carcinoma Following Surgical Resection Depends on Their Localization and Tumor Size.
Wang Q; Luan W; Warren L; Fiel MI; Blank S; Kadri H; Mandeli J; Hiotis SP
J Immunother; 2016 Jan; 39(1):36-44. PubMed ID: 26641260
[TBL] [Abstract][Full Text] [Related]
18. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
19. Recurrent hepatocellular carcinoma cells with stem cell-like properties: possible targets for immunotherapy.
Xu X; Xing B; Hu M; Xu Z; Xie Y; Dai G; Gu J; Wang Y; Zhang Z
Cytotherapy; 2010 Apr; 12(2):190-200. PubMed ID: 19929456
[TBL] [Abstract][Full Text] [Related]
20. [CD4 TIL (Tumor Infiltrating Lymphocytes) induce complete response in patients treated with IL-2 (Interleukin-2). Preliminary study].
Thiounn N; Mathiot C; Flam T; Tartour E; Peyret C; Joyeux I; Abecassis JP; Zerbib M; Fridman WH; Debré B
J Urol (Paris); 1994; 100(4):185-8. PubMed ID: 7868930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
